AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30706431
Drug: Counseling about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling about GI events and recommendations for DMF administration
Trial: 30706431
Drug: Symptomatic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapies for GI AEs
Trial: 30706490
Drug: Twice-weekly prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly prednisolone (5 mg/kg/dose)
Trial: 30706561
Drug: Residents with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residents with psychosis without antipsychotic medication
Trial: 30708264
Drug: T-DM1 (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DM1 (3.6 mg/kg every 3 weeks)
Trial: 30709364
Drug: Intrathecal delivery
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal delivery of a viral vector in a Phase I gene therapy clinical trial for GAN.
Trial: 30709417
Drug: Alerts regarding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alerts regarding potentially inappropriate DOAC doses
Trial: 30709417
Drug: Alerts regarding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alerts regarding potentially inappropriate concomitant antiplatelet agents
Trial: 30709417
Drug: Alerts regarding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alerts regarding other drug related problems
Trial: 30709431
Drug: Ublituximab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ublituximab (900 mg IV), Umbralisib (800 mg orally once daily), Ibrutinib (420 mg for CLL, 560 mg for NHL)
Trial: 30709431
Drug: Ublituximab, Umbralisib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ublituximab, Umbralisib, and Ibrutinib combination
Trial: 30710527
Drug: Treg cells
RxNorm normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treg cells incubated with rapamycin and RARA agonist (RAR568)
Trial: 30711772
Drug: BAY 1238097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1238097 at 10 mg/week
Trial: 30711772
Drug: BAY 1238097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1238097 at 40 mg/week
Trial: 30711772
Drug: BAY 1238097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1238097 at 80 mg/week
Trial: 30711772
Drug: BAY 1238097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1238097 (all doses)
Trial: 30713028
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma vitamin E levels with high selenium levels (median≥83.7 μg/L)
Trial: 30713028
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma vitamin E levels with low selenium levels (<83.7 μg/L)
Trial: 30713498
Drug: Rituximab (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (initially at a low dose of 150 mg/m2)
Trial: 30713498
Drug: Immunoglobulin dose
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin dose escalation
Trial: 30713538
Drug: Chimpanzee adenoviral
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimpanzee adenoviral vectors vaccine
Trial: 30713786
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ONCOS-102 and pembrolizumab
Trial: 30713786
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 µg or 400 µg)
Trial: 30714202
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus clinical management
Trial: 30716769
Drug: Compounded pain
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounded pain creams for neuropathic pain (ketamine, gabapentin, clonidine, and lidocaine)
Trial: 30716769
Drug: Compounded pain
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounded pain creams for nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine)
Trial: 30716769
Drug: Compounded pain
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounded pain creams for mixed pain (ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine)
Trial: 30716769
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (compounded pain creams)
Trial: 30718242
Drug: Day 0
RxNorm normalized name: Apri 28-Day 0.03mg-0.15mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0 to 100 mean glucose of 100 to 124 mg/dL
Trial: 30718519
Drug: Inhaled corticosteroid/long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid/long-acting β agonists prescribed as per usual clinical practice
Trial: 30718541
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) treatment
Trial: 30720784
Drug: Park prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Park prescription intervention including an information pack, access to a weekly group exercise program in parks, and telephone counselling.
Trial: 30721341
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal
Trial: 30721554
Drug: High-sensitivity troponin
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity troponin (hscTnT) ≤ 5 ng/L
Trial: 30721554
Drug: High-sensitivity troponin
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity troponin (hscTnT) > 50 ng/L
Trial: 30721554
Drug: Natriuretic peptide
RxNorm normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natriuretic peptide (NT-proBNP) ≤ 125 ng/L
Trial: 30721554
Drug: Natriuretic peptide
RxNorm normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natriuretic peptide (NT-proBNP) > 2,000 ng/L
Trial: 30721917
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of acidified milk (800 g) containing 38.8 g lactose
Trial: 30722097
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg azithromycin thrice weekly for 12 weeks
Trial: 30723079
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels of TARC, MDC, and IL-10 after therapy
Trial: 30723079
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels of TARC and IL-10 after therapy
Trial: 30723727
Drug: Observational study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational study data collection including clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs), and healthcare utilization (HCU) collected yearly and 3-monthly.
Trial: 30724734
Drug: EA-230 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA-230 (90 mg/kg/hour)
Trial: 30724759
Drug: Once-daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)
Trial: 30724759
Drug: Smartphone video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone video dosing
Trial: 30725293
Drug: Tenofovir Disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir Disoproxil Fumarate (TDF) therapy for 144 weeks
Trial: 30756308
Drug: BI 853520
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 853520 200 mg QD
Trial: 30726175
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg/kg every 3 weeks for up to 2 years)
Trial: 30727950
Drug: Male partners
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Male partners receiving syphilis notification and treatment after partner notification by infected pregnant women.
Trial: 30728310
Drug: robot-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: robot-based therapy targeting finger movements with enhanced proprioceptive feedback for 3 weeks
Trial: 30729531
Drug: CD19-directed CAR
RxNorm normalized name: Allogeneic gene-edited CD19-directed CAR T cells/azercabtagene zapreleucel
DrugBank: Azercabtagene zapreleucel (DB17185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-directed CAR T-cell therapy
Trial: 30729531
Drug: Precollection platelets
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precollection platelets (every 10 × 10^9/L increase)
Trial: 30730411
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors in cancers with increased tumor mutational burden
Trial: 30731276
Drug: Durvalumab 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 10 mg/kg intravenously every 2 weeks for 12 months
Trial: 30733270
Drug: Twice-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly carfilzomib at 27 mg/m2
Trial: 30733270
Drug: Twice-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly carfilzomib at 56 mg/m2
Trial: 30734042
Drug: Endovascular thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombectomy plus standard medical therapy
Trial: 30735255
Drug: Acute intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intravenous alcohol infusion
Trial: 30735474
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine adoption at no-cost
Trial: 30735474
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine adoption with cost (25€ per person)
Trial: 30736852
Drug: Allogenic γδ
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogenic γδ T cell immunotherapy (8 infusions from August 2017 to February 2018)
Trial: 30738407
Drug: CoGNIT (Computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoGNIT (Computerized General Neuropsychological INPH Test) administered preoperatively and at a postoperative follow-up 4 months after shunt surgery
Trial: 30739366
Drug: Ruzasvir 60
RxNorm normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruzasvir 60 mg plus Uprifosbuvir 450 mg
Trial: 30739576
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel oral suspension (≤0.18 mg/kg/d)
Trial: 30740545
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation (NMES) treatments lasting 20-45 minutes twice weekly for 2-4 months during feeding therapy sessions by a trained occupational therapist (OT).
Trial: 30741382
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide extended-release (TA-ER) injection
Trial: 30741812
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (400 mg once a day)
Trial: 30742211
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (n=1414)
Trial: 30742211
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (n=1422)
Trial: 30742566
Drug: Duvelisib 25
RxNorm normalized name: duvelisib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death
Trial: 30742776
Drug: Simultaneous practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous practice of diet, art, and biofield therapy
Trial: 30742776
Drug: Biofield therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofield therapy
Trial: 30743197
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of microcephaly and major ultrasound abnormalities
Trial: 30744442
Drug: Minocycline (Tier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (Tier 1: 800 mg loading dose followed by 200 mg BID for 7 days)
Trial: 30744442
Drug: Minocycline (Tier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (Tier 2: 800 mg loading dose followed by 400 mg BID for 7 days)
Trial: 30745090
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks (recommended phase 2 dose)
Trial: 30745090
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks
Trial: 30745365
Drug: Autologous lymphocyte
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous lymphocyte infusion combined with peri-autoSCT immunotherapy with recombinant MAGE-A3 and adjuvant
Trial: 30746241
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose from CBCT
Trial: 30746608
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg BID (DE110)
Trial: 30746608
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg BID (DE150)
Trial: 30746608
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from Warfarin to Dabigatran
Trial: 30747243
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous IL-2 (125,000 IU/kg/day, maximum 9-10 doses over 2 weeks)
Trial: 30747243
Drug: Non-myeloablative lymphodepleting
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-myeloablative lymphodepleting chemotherapy, TIL, and low-dose IL-2
Trial: 30747243
Drug: TIL infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIL infusion product monitoring
Trial: 30747273
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and mechanical stabilization
Trial: 30747719
Drug: Incentives for
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Incentives for adherence to antidepressant medications in the first 6 weeks of treatment (Project 1: ADAPT)
Trial: 30753549
Drug: Tryptophan intake
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan intake ranging from 0.5 to 9.75 mg.kg-1.d-1
Trial: 30753611
Drug: IMA950/poly-ICLC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMA950/poly-ICLC vaccine
Trial: 30753685
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements (DS)
Trial: 30755498
Drug: Pressurised intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Trial: 30755498
Drug: PIPAC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC treatment response
Trial: 30755907
Drug: Obinutuzumab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab (initial test dose)
Trial: 30756297
Drug: 100% pasteurized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% pasteurized watermelon juice (360 ml)
Trial: 30756308
Drug: BI 853520
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 853520 200 mg once daily (QD)
Trial: 30758653
Drug: ab interno
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ab interno subconjunctival gelatin implant (phaco + implant)
Trial: 30758653
Drug: ab interno
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ab interno subconjunctival gelatin implant (implant alone)
Trial: 30760105
Drug: Repeatedly measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeatedly measured biomarkers (suppression of tumorigenicity-2, galectin-3, galectin-4, growth differentiation factor-15, matrix metalloproteinase-2 and 9, tissue inhibitor metalloproteinase-4, perlecan, cathepsin-D, cystatin-B)
Trial: 30760246
Drug: Biomarkers measuring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarkers measuring cancer risk (insulin resistance, inflammation, oxidative stress)
Trial: 30760466
Drug: Pracinostat 60
RxNorm normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pracinostat 60 mg/d, 3 d/wk for 3 consecutive weeks plus azacitidine 75 mg/m²
Trial: 30761059
Drug: Adapted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted cognitive behavioral treatment
Trial: 30761078
Drug: Smart Device
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart Device System (SDS) including smartphone-based questionnaires, two smartwatches, and tablet-based Archimedean spirals drawing
Trial: 30762508
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg once daily)
Trial: 30764793
Drug: HPP patients
RxNorm normalized name: 4-HPP
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HPP patients (regardless of prior or current treatment)
Trial: 30764800
Drug: High indoxyl
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High indoxyl sulfate (IS) group (IS level ≥ 2.74 μg/ml)
Trial: 30764800
Drug: Low indoxyl
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low indoxyl sulfate (IS) group (IS level < 2.74 μg/ml)
Trial: 30764800
Drug: Indoxyl sulfate
RxNorm normalized name: SULFATE
DrugBank: Indoxyl sulfate (DB07992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoxyl sulfate level ≥ 2.74 μg/ml
Trial: 30765123
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals
Trial: 30765258
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 2
Trial: 30765258
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg/kg and 10 mg/kg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 1b
Trial: 30766492
Drug: Vortioxetine, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine, dosage and duration not available
Trial: 30767431
Drug: cfDNA from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cfDNA from combination of plasma, sputum, and urine
Trial: 30767706
Drug: Isoniazid (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (dosage not specified)
Trial: 30767706
Drug: Rifampicin (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (dosage not specified)
Trial: 30768838
Drug: elbasvir/grazoprevir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elbasvir/grazoprevir treatment after recipient HCV was first detected
Trial: 30770221
Drug: MenB-FHbp vaccine
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenB-FHbp vaccine (120 μg) administered in various schedules (0-, 1-, 6-month; 0-, 2-, 6-month; 0-, 6-month; 0-, 2-month; or 0-, 4-month)